NCT01644396View on ClinicalTrials.gov

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
BIOLOGICAL

Adalimumab

Trial Locations (7)

107076

Site Reference ID/Investigator# 67542, Moscow

190013

Site Reference ID/Investigator# 78413, Saint Petersburg

194044

Site Reference ID/Investigator# 67545, Saint Petersburg

214018

Site Reference ID/Investigator# 78417, Smolensk

410028

Site Reference ID/Investigator# 67546, Saratov

420012

Site Reference ID/Investigator# 78433, Kazan'

620076

Site Reference ID/Investigator# 67547, Yekaterinburg

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01644396 - An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation | Biotech Hunter | Biotech Hunter